CY1108670T1 - Αναλογα λιποξινης ως νεοι αναστολεις αγγειογενεσης - Google Patents

Αναλογα λιποξινης ως νεοι αναστολεις αγγειογενεσης

Info

Publication number
CY1108670T1
CY1108670T1 CY20081101498T CY081101498T CY1108670T1 CY 1108670 T1 CY1108670 T1 CY 1108670T1 CY 20081101498 T CY20081101498 T CY 20081101498T CY 081101498 T CY081101498 T CY 081101498T CY 1108670 T1 CY1108670 T1 CY 1108670T1
Authority
CY
Cyprus
Prior art keywords
suspensions
lxa
lipoxin analogs
new angiogenesis
epi
Prior art date
Application number
CY20081101498T
Other languages
Greek (el)
English (en)
Inventor
Charles N Serhan
Iolanda M Fierro
Original Assignee
The Brigham And Women΄S Hospital, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Brigham And Women΄S Hospital, Inc. filed Critical The Brigham And Women΄S Hospital, Inc.
Publication of CY1108670T1 publication Critical patent/CY1108670T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20081101498T 2001-03-02 2008-12-29 Αναλογα λιποξινης ως νεοι αναστολεις αγγειογενεσης CY1108670T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27293101P 2001-03-02 2001-03-02
EP02721234A EP1406698B1 (en) 2001-03-02 2002-03-01 Lipoxin analogs as novel inhibitors of angiogenesis
US10/086,609 US6627658B2 (en) 2001-03-02 2002-03-01 Lipoxin analogs as novel inhibitors of angiogenesis

Publications (1)

Publication Number Publication Date
CY1108670T1 true CY1108670T1 (el) 2014-04-09

Family

ID=26774943

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101498T CY1108670T1 (el) 2001-03-02 2008-12-29 Αναλογα λιποξινης ως νεοι αναστολεις αγγειογενεσης

Country Status (11)

Country Link
US (4) US6627658B2 (enExample)
EP (2) EP2221089A1 (enExample)
JP (3) JP2005508282A (enExample)
AT (1) ATE412448T1 (enExample)
AU (1) AU2002252175A1 (enExample)
CY (1) CY1108670T1 (enExample)
DE (1) DE60229640D1 (enExample)
DK (1) DK1406698T3 (enExample)
ES (1) ES2316553T3 (enExample)
PT (1) PT1406698E (enExample)
WO (1) WO2002070068A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1762557B1 (en) 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US7700650B2 (en) 2000-03-20 2010-04-20 Trustees Of Boston University Lipoxin analogs and method for the treatment of periodontal disease
DE60229640D1 (de) * 2001-03-02 2008-12-11 Brigham & Womens Hospital Lipoxin analoge als neue inhibitoren der angiogenese
US8722654B2 (en) 2001-03-02 2014-05-13 The Brigham And Women's Hospital, Inc. Lipoxin analogs as novel inhibitors of angiogenesis
US7902257B2 (en) * 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
WO2004014835A2 (en) * 2002-08-12 2004-02-19 Brigham And Women's Hospital Resolvins: biotemplates for therapeutic interventions
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
WO2004078143A2 (en) * 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
US20050238589A1 (en) * 2004-04-14 2005-10-27 Van Dyke Thomas E Methods and compositions for preventing or treating periodontal diseases
EP1809270B1 (en) * 2004-11-09 2010-03-24 Alcon Inc. 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
WO2007041440A2 (en) * 2005-10-03 2007-04-12 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
WO2007061783A1 (en) * 2005-11-18 2007-05-31 Trustees Of Boston University Treatment and prevention of bone loss using resolvins
CA2650607A1 (en) * 2006-04-28 2007-11-08 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of cardiovascular disease
EP2049099A1 (en) * 2006-07-19 2009-04-22 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of mucositis
EP2131833A2 (en) * 2006-10-26 2009-12-16 Resolvyx Pharmaceuticals, Inc. Use of resolvins for inhibition of bone loss
WO2008070129A2 (en) * 2006-12-05 2008-06-12 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
EP2184993B1 (en) * 2007-08-08 2011-10-19 Basf Se Aqueous microemulsions containing organic insecticide compounds
EP2207543A2 (en) * 2007-09-14 2010-07-21 Resolvyx Pharmaceuticals, Inc. Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for treating autoimmune diseases or inhibiting immune function
US20090118243A1 (en) * 2007-10-12 2009-05-07 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of ophthalmic conditions
EP2219638A2 (en) * 2007-10-29 2010-08-25 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Lipoxin a4 protection for retinal cells
US7601693B2 (en) * 2008-02-05 2009-10-13 National Taiwan University Composition for treating cancer and use thereof
US20100105772A1 (en) * 2008-04-25 2010-04-29 Serhan Charles N Use of novel lipid mediators to inhibit angiogenesis
AU2014218666B2 (en) * 2013-02-22 2018-11-01 University Of Southern California Methods for treatment of ophthalmic diseases and disorders
KR20160048029A (ko) 2013-03-15 2016-05-03 마르쿠스 카레 토를레이프 라르손 제대혈 수집 및 세포의 분리를 위한 세포, 방법 및 장치
EP3020398A1 (en) * 2014-11-17 2016-05-18 Nitto Denko Corporation Compounds and formulations for reducing scarring
US10130719B2 (en) 2016-06-03 2018-11-20 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
WO2018073615A1 (en) 2016-10-21 2018-04-26 Longboat Explorers Ab Methods and compositions for generating hematopoietic cells
WO2018144316A1 (en) 2017-01-31 2018-08-09 The Brigham And Women's Hospital, Inc. Alx receptor ligands define a biochemical endotype for inflammation-based diseases
CA3055093A1 (en) * 2017-03-09 2018-09-13 University Health Network Lipoxin and lipoxin analogue mediated neuroprotection and treatments
US12465878B2 (en) 2019-06-20 2025-11-11 Amniotics Ab Apparatus for filtering amniotic fluid
CN114765957B (zh) 2019-10-18 2025-09-12 Amniotics公司 从羊水中获得羊膜间充质干细胞的方法和设备及其来源的细胞
US12435308B2 (en) 2020-11-06 2025-10-07 Amniotics Ab Immunomodulation by amniotic fluid mesenchymal stem cells
KR20240150603A (ko) 2022-03-03 2024-10-15 테티스 파마수티컬스 엘엘씨 특수화된 해소촉진 매개체의 시클로덱스트린 복합체

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560514A (en) 1984-05-04 1985-12-24 Bengt Samuelsson Inflammatory lipoxin A and anti-anflammatory lipoxin B compounds
US4576758A (en) 1984-06-01 1986-03-18 The Upjohn Company Anti-inflammatory lipoxin B analogs
US4780281A (en) 1985-06-14 1988-10-25 Wayne State University Method for assay of peroxidase enzyme or reducing substrate activity
JPS62198677A (ja) 1986-02-26 1987-09-02 Nissan Chem Ind Ltd テトラオ−ル誘導体
JPH0739368B2 (ja) 1986-10-01 1995-05-01 旭硝子株式会社 ２０，２０，２０−トリフルオロアラキドン酸誘導体およびその製造法
CA1329809C (en) 1987-07-08 1994-05-24 Nissan Chemical Industries, Ltd. Optically active allyl alcohol and process for producing leucotriene b_ using thereof
JPH01228994A (ja) 1988-03-10 1989-09-12 Fumie Satou γ−シリルアリルアルコール及びその製造法
US5079261A (en) 1989-04-28 1992-01-07 Brigham And Women's Hospital Use of lipoxin a4 and its derivatives as antagonists for slow-reacting substances of anaphylaxis
JP2834512B2 (ja) 1990-01-30 1998-12-09 帝人株式会社 リポキシン誘導体を有効成分とする疾患治療剤
US5322699A (en) 1991-02-04 1994-06-21 The Rockefeller University Leukocyte-derived CR3 modulator, integrin modulating factor-1 (IMF-1)
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
JP3227922B2 (ja) 1993-01-20 2001-11-12 富士電機株式会社 自動販売機
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
US5441951A (en) 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
EP1657233A1 (en) 1993-06-15 2006-05-17 The Brigham & Women's Hospital, Inc. Lipoxin compounds
AU7215294A (en) * 1993-06-29 1995-01-24 Brigham And Women's Hospital Modulation of inflammation related to columnar epithelia
US5750354A (en) 1994-03-11 1998-05-12 Brigham And Women's Hospital Lipoxin transport system and uses therefor
EP0938557B1 (en) * 1996-10-25 2000-09-13 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian cd97 alpha subunit
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
WO2000009503A1 (en) * 1998-08-13 2000-02-24 Merck & Co., Inc. Integrin receptor antagonists
CA2615917C (en) * 1999-03-18 2011-10-04 Brigham And Women's Hospital Use of lipoxin compounds for inhibiting of tnf-(alpha)initiated neutrophil response
HK1043357B (en) * 1999-03-18 2005-12-09 The Brigham And Women's Hospital, Inc. LIPOXIN compound and its use
EP1762557B1 (en) * 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US7700650B2 (en) 2000-03-20 2010-04-20 Trustees Of Boston University Lipoxin analogs and method for the treatment of periodontal disease
DE60229640D1 (de) 2001-03-02 2008-12-11 Brigham & Womens Hospital Lipoxin analoge als neue inhibitoren der angiogenese

Also Published As

Publication number Publication date
WO2002070068A2 (en) 2002-09-12
JP2010059183A (ja) 2010-03-18
US6627658B2 (en) 2003-09-30
EP1406698A2 (en) 2004-04-14
DE60229640D1 (de) 2008-12-11
EP2221089A1 (en) 2010-08-25
US20080064749A1 (en) 2008-03-13
WO2002070068A3 (en) 2003-12-31
ATE412448T1 (de) 2008-11-15
AU2002252175A1 (en) 2002-09-19
JP2012255025A (ja) 2012-12-27
DK1406698T3 (da) 2009-02-09
EP1406698B1 (en) 2008-10-29
JP2005508282A (ja) 2005-03-31
JP5302856B2 (ja) 2013-10-02
US20060009521A1 (en) 2006-01-12
ES2316553T3 (es) 2009-04-16
PT1406698E (pt) 2009-01-12
US20040053998A1 (en) 2004-03-18
US8008282B2 (en) 2011-08-30
US20020193431A1 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
CY1108670T1 (el) Αναλογα λιποξινης ως νεοι αναστολεις αγγειογενεσης
PT1780197E (pt) 5-substituinte-2-fenilamino benzamida como inibidor de mek
BR9810841A (pt) Inibidores de metaloprotease alicìclicos
MXPA03010435A (es) Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes.
FI941767A0 (fi) 1H-indoli-3-asetamidi sPLA2 inhibiittoreita
GR3031917T3 (en) Treatment of diseases caused by sebaceous gland disorders with acyl CoA cholesterol acyl transferase inhibitors
ES2148305T3 (es) Derivados de aminoacidos ciclicos que tienen actividad inhibidora de ace y nep.
BG105163A (bg) Използване на аналог на валпроева киселина за лечение и профилактика на мигрена и афективни заболявания
BG106407A (en) Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof
EA200100930A1 (ru) Способ лечения хозл
DE60236467D1 (de) Lipoxinanaloge als neuartige Restenose-Hemmer
ATE352317T1 (de) Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktiven bestandteilen
ES2147499A1 (es) Derivados de acidos carboxilicos, metodo para su elaboracion y agentes terapeuticos que contienen estos compuestos.
DE60004996D1 (de) Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen
IL156203A0 (en) Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders
AP2003002905A0 (en) Sertraline salts and sustained-release dosage forms of sertraline.